Medicalization of psychedelics

Medicalization of psychedelics is the effort to make their use legitimate and available through clinical treatment, but it is not simply a change in legal or professional status. It also defines what counts as an acceptable purpose, who may guide an experience, and whether its effects can be understood apart from the surrounding therapeutic and social context. The book presents medicalization as both a route back from prohibition and a contested boundary: clinical acceptance may widen access, while limiting psychedelics to the sick risks excluding the broader purposes that helped make them culturally significant.

An Older Dispute Over What Treatment Means

The conflict predates the recent research revival. In the mid-1950s, Al Hubbard, Humphry Osmond, and Aldous Huxley advanced a psychedelic model of therapy that challenged psychiatry’s established categories. Earlier models were easier to accommodate: psychotomimetic drugs were understood through their resemblance to psychosis, while psycholytic use could be treated as an adjunct to psychoanalysis. Psychedelic therapy proposed something different: a single high-dose session intended to produce a conversion-like experience, requiring a new understanding of the roles of both patient and therapist. Its spiritual associations and emphasis on set and setting also complicated the profession’s claim to a strictly medical, biochemical account of the mind.

The institutional divisions were visible beyond the therapy room. Al Hubbard’s Commission for the Study of Creative Imagination, established in 1955, reflected his interest in taking psychedelic work beyond medicine’s focus on illness. Sidney Cohen resigned from its board in 1957, a year after joining. Hubbard’s own increasing distance from science as an end in itself signaled a wider shift: the purposes proposed for psychedelic research were expanding from psychotherapy toward cultural change. Medicalization therefore had a contested history from the outset, rather than a single clinical definition waiting to be restored.

The book frames the different approaches as attempts to build a social container for powerful drugs. Psychotomimetic, psycholytic, psychedelic, and later entheogenic models each joined protocols for use to a theory of what the experience meant. The risk, in this account, was not that psychedelics must be inherently ungovernable, but that an unguided, do-it-yourself approach could discard the structures meant to manage their effects. Psychedelic therapy, especially the Hubbard method, was an effort to create a Western form of guided practice. Medicalization is thus connected to a practical question of care and oversight as well as to disputes over scientific legitimacy.

Clinical Evidence and the Problem of Isolation

The modern trials renewed the case for medical treatment while exposing difficulties in fitting psychedelics to conventional research methods. Participants and guides can often tell whether psilocybin or a placebo has been administered, making blinding difficult. Researchers also have trouble separating the drug’s effects from set and setting, the therapists’ presence, and participants’ expectations. These factors are not incidental in psychedelic treatment: the experience is shaped by them, even as standard drug research seeks to isolate a single variable. The resulting challenge is conceptual as well as technical, since the treatment may work partly by occasioning a particular kind of experience rather than through a narrowly pharmacological action.

The 2016 results from the New York University and Johns Hopkins University cancer studies gave the renewed clinical effort substantial momentum. Across the two trials, about 80 percent of patients showed clinically significant reductions in anxiety and depression, and those reductions lasted at least six months. The intensity of the reported mystical experience closely tracked the degree of symptom relief. Yet the studies involved only 80 subjects altogether, and larger trials would be needed before the government would consider rescheduling psilocybin and approving the treatment. The findings prompted requests for further research from dozens of medical schools, new funding, and a shift in institutional attitudes: New York University moved the treatment room from its dental college toward the main hospital, while its cancer center sought a room for a future trial.

The research did not settle how to explain the results. The relationship between mystical experience and symptom relief might involve a diminished sense of self, heightened meaning, or other psychological and neurobiological processes; no single biological, psychological, philosophical, or spiritual vocabulary had established a final account. A follow-up study of New York University participants emphasized connection to loved ones and a movement from separateness toward interconnectedness. Patients described joy, bliss, and love, and difficult passages during sessions were often followed by surrender and acceptance, including acceptance of their cancers. This account foregrounded psychotherapy and relationships alongside the drug, rather than treating the molecule as an isolated intervention.

A Return to Medicine, Not a Resolution

As psychedelic treatment re-entered respectable research, the book describes a frontier between clinical science and spiritual practice. Charles Grob calls the approach applied mysticism; other researchers have argued that strict scientific methods alone may not be sufficient and that shamanic examples can inform the careful orchestration of nonpharmacological factors. These positions do not erase the differences between medicine and religion. They show why medical acceptance remains uneasy: the experience being evaluated may include forms of meaning and transformation that conventional clinical language does not readily contain.

The underground offers a contrasting picture of practice during the period when sanctioned therapy had ended. The author describes perhaps a couple hundred guides working with psychedelic substances in prescribed ways, with aims that included healing illness and helping healthy people develop spiritual, creative, or emotional potential. Some were credentialed therapists or religious professionals; others came from varied therapeutic and alternative traditions. Their work remained illegal, and guides asked that their names and locations be concealed. The author changed identifying details while emphasizing that the people described were real, not composites. This hidden practice preserved forms of guidance and treatment outside formal medical institutions, but at the cost of legal and professional risk.

The renewed clinical path also faces economic and regulatory obstacles. Phase 3 trials require multiple sites and hundreds of volunteers and may cost tens of millions of dollars. Pharmaceutical companies have shown little interest: psilocybin is a natural product, the LSD patent expired decades ago, and a treatment that might be taken once in a lifetime offers a different business prospect from medication for chronic conditions. Psychiatry, too, is organized around recurring prescriptions or weekly therapy, whereas a psychedelic session lasts several hours and usually requires two therapists to remain present. If successful treatment does not generate frequent repeat visits, neither the clinical nor commercial model is straightforward.

The Scope of Legitimate Use

The argument over medicalization is also an argument over whom psychedelic treatment is for. Bob Jesse worries that treating medicine as the one legitimate route would be a mistake. Katherine MacLean imagines a psychedelic hospice in which dying people and their loved ones could use psychedelics together, rather than keeping treatment confined to the patient. The proposal unsettles colleagues who favor a narrower medical frame, but it follows the book’s broader concern that these experiences may matter to healthy people as well as the ill.

Other visions range from carefully guided, multigenerational settings resembling religious communities to occasional, supportive spaces for people seeking treatment, spiritual exploration, or simple curiosity. The differences are consequential: medicalization can create regulated settings, trained practitioners, and a path toward public legitimacy, while broader approaches resist making diagnosis the sole gateway to access. The book does not treat these aims as interchangeable, nor does it present clinical recognition as the end of the dispute. It asks whether medical institutions can accommodate a practice whose purposes extend beyond illness without stripping away the guidance and integration that proponents consider essential.

Training and integration are part of that question. In late 2016, the California Institute of Integral Studies graduated its first class of 42 psychedelic therapists; some underground practitioners feared that legalization would leave them behind. Meanwhile, advocates across clinical and less narrowly medical settings stressed the need for well-trained guides and help integrating experiences afterward. A spiritual or otherwise powerful session, on its own, does not guarantee a lasting change. Medicalization, in the account presented here, is therefore neither merely a badge of respectability nor a settled destination. It is an ongoing negotiation over evidence, care, authority, and the range of human purposes for which psychedelic experiences may be used.